清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

医学 富马酸福莫特罗 干粉吸入器 布地奈德 计量吸入器 慢性阻塞性肺病 福莫特罗 丙酸氟替卡松 吸入器 随机对照试验 内科学 哮喘 麻醉
作者
Gary T. Ferguson,Klaus F. Rabe,Fernando J. Martínez,Leonardo M. Fabbri,Chen Wang,Masakazu Ichinose,Eric Bourne,Shaila Ballal,Patrick Darken,Kiernan DeAngelis,Magnus Aurivillius,Paul Dorinsky,Colin Reisner
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:6 (10): 747-758 被引量:408
标识
DOI:10.1016/s2213-2600(18)30327-8
摘要

Background Inhaled corticosteroids have been used in patients with chronic obstructive pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not well known. We aimed to compare the efficacy of a triple therapy with corresponding dual therapies in symptomatic patients with moderate to very severe COPD, without a requirement for a history of exacerbations. Methods In this double-blind, parallel-group, multicentre phase 3 randomised controlled trial, we recruited patients from hospitals and care centres in Canada, China, Japan, and the USA. Eligible patients were 40–80 years of age, were current or former smokers (with a smoking history of ≥10 pack-years), had an established clinical history of COPD, and were symptomatic for COPD, despite receiving two or more inhaled maintenance therapies for at least 6 weeks before screening. We randomly assigned patients (2:2:1:1) using an interactive web response system to receive budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler 320/18/9·6 μg (BGF MDI), glycopyrrolate/ formoterol fumarate metered-dose inhaler 18/9·6 μg (GFF MDI), budesonide/formoterol fumarate metered-dose inhaler 320/9·6 μg (BFF MDI), or open-label budesonide/formoterol fumarate dry-powder inhaler 400/12 μg (BUD/ FORM DPI). Primary endpoints for the Europe/Canada statistical analysis approach were FEV1 area under the curve from 0–4 h (AUC0–4) for BGF MDI versus BFF MDI and BGF MDI versus BUD/FORM DPI over 24 weeks; and change from baseline in morning pre-dose trough FEV1 for BGF MDI versus GFF MDI and non-inferiority of BFF MDI versus BUD/FORM DPI (margin of −50 mL from lower bound of 95% CI) over 24 weeks. Comparisons with BUD/FORM DPI were made for the Europe/Canada statistical analysis approach only. This study is registered with ClinicalTrials.gov, number NCT02497001. Findings Between Aug 20, 2015, and Jan 5, 2018, 3047 patients were screened from 215 sites, and 1902 were randomly assigned to receive BGF MDI (n=640), GFF MDI (n=627), BFF MDI (n=316), or BUD/FORM DPI (n=319). Over 24 weeks, BGF MDI significantly improved FEV1 AUC0–4 versus BFF MDI (least squares mean difference 104 mL, 95% CI 77 to 131; p<0·0001) and BUD/FORM DPI (91 mL, 64 to 117; p<0·0001). BGF MDI also significantly improved pre-dose trough FEV1 versus GFF MDI (22 mL, 4 to 39; p=0·0139) and BFF MDI was non-inferior to BUD/FORM DPI (−10 mL, −36 to 16; p=0·4390). At week 24, patients in the BGF MDI group had a significantly improved FEV1 AUC0–4 compared with patients receiving BFF MDI (116 mL, 95% CI 80 to 152; p<0·0001); there was a non-significant improvement in the change from baseline in morning pre-dose trough FEV1 at week 24 versus GFF MDI (13 mL, −9 to 36 mL; p=0·2375). The most common treatment-emergent adverse events were nasopharyngitis (n=49 [8%] in the BGF MDI group; n=41 [7%] in the GFF MDI group; n=26 [8%] in the BFF MDI group; and n=30 [9%] in the BUD/FORM DPI group) and upper respiratory tract infection (n=65 [10%]; n=38 [6%]; n=18 [6%]; and n=22 [7%]). Pneumonia incidence was low (<2%) and similar across treatments. There were two treatment-related deaths, both in the GFF MDI group. Interpretation BGF MDI was efficacious, well tolerated, and could be a more appropriate treatment than the corresponding dual therapies for symptomatic patients with moderate to very severe COPD, irrespective of exacerbation history. Funding Pearl—a member of the AstraZeneca Group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科目三的应助被TingtingGZ采纳,获得10
8秒前
多情莫言完成签到,获得积分10
8秒前
无私的世界完成签到 ,获得积分10
11秒前
19秒前
TingtingGZ发布了新的文献求助10
23秒前
神勇友安完成签到,获得积分10
28秒前
云裳完成签到,获得积分10
47秒前
星辰大海的应助被chenchen采纳,获得10
58秒前
Wang发布了新的文献求助10
1分钟前
复杂曼荷完成签到,获得积分10
1分钟前
无奈的绾绾完成签到,获得积分10
1分钟前
1分钟前
Myownway完成签到 ,获得积分10
1分钟前
1分钟前
tuimao发布了新的文献求助10
1分钟前
科研通AI6.3的应助被TingtingGZ采纳,获得10
1分钟前
受伤青丝完成签到,获得积分10
1分钟前
1分钟前
甜美凝琴完成签到,获得积分10
1分钟前
廖道罡完成签到,获得积分10
1分钟前
TingtingGZ发布了新的文献求助10
1分钟前
1分钟前
chenchen发布了新的文献求助10
1分钟前
温暖冬日完成签到,获得积分10
1分钟前
2分钟前
2分钟前
忐忑的凝云完成签到,获得积分10
2分钟前
从容美女发布了新的文献求助10
2分钟前
欢呼安露完成签到,获得积分10
2分钟前
Wang完成签到 ,获得积分20
2分钟前
乐乐的应助被tuimao采纳,获得10
2分钟前
无私的碧玉完成签到,获得积分10
2分钟前
丰富的德天完成签到 ,获得积分10
2分钟前
科研通AI6.4的应助被TingtingGZ采纳,获得10
2分钟前
简单完成签到 ,获得积分10
3分钟前
外向的慕山完成签到,获得积分10
3分钟前
笨笨盈完成签到,获得积分10
3分钟前
3分钟前
NN完成签到,获得积分10
3分钟前
等待戈多发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173213
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780496
捐赠科研通 7767342
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476697